Dose-Intensive Chemotherapy Combined with Hematopoietic Stem Cell Transplantation in Refractory Germ Cell Tumors.
|
Accession number;99A0233520
|
| Title;Dose-Intensive Chemotherapy Combined with Hematopoietic Stem Cell Transplantation in Refractory Germ Cell Tumors. |
| Author;
KASAOKA YOSHINOBU
(Hiroshima Univ., Sch. of Med.)
NAKAMOTO TAKAHISA
(Hiroshima Univ., Sch. of Med.)
USUI TSUGURU
(Hiroshima Univ., Sch. of Med.)
HYODO HIDEO
(Res. Inst. for Nucl. Med. and Biol., Hiroshima Univ.)
KIMURA AKIRO
(Res. Inst. for Nucl. Med. and Biol., Hiroshima Univ.)
HINO YOSHIHIKO
(Res. Inst. for Nucl. Med. and Biol., Hiroshima Univ.)
|
Journal Title;Nishinihon Journal of Urology
|
Journal Code:Z0253B
|
ISSN:0029-0726
|
|
VOL.61;NO.1;PAGE.1-5(1999)
|
| Figure&Table&Reference;FIG.2, TBL.3, REF.12 |
| Pub. Country;Japan |
| Language;Japanese |
| Abstract;We report 5 cases of refractory germ cell tumor treated by dose-intensive chemotherapy combined with hematopoietic stem cell transplantation. The patients were 22 to 58 years old, and all had multiple pulmonary metastases with or without a bulky retroperitoneal lymph node mass. One of them had an extragonadal germ cell tumor. For the collection of peripheral blood stem cells, 4 patients were given cisplatin and etoposide while the remaining patient received high-dose etoposide alone. Dose-intensive chemotherapy comprised carboplatin and etoposide with cyclophosphamide or ifosfamide. The number of granulocyte-macrophage colony-forming units in the transferred cells varied from 0.47 to 81.0*104/kg. For one patient, 6.8*107/kg of CD 34-positive cells were transplanted. Three patients obtained a partial response while two continued to have stable disease, however only two patients remained alive with disease for the duration of 45 and 24 months. Our experience presented here certainly showed that one or two cycles of dose-intensive chemotherapy combined with hematopoietic stem cell transplantation can be administered quite safely, although a new regimen which can provide more effective results needs to be developed. (author abst.) |
|
|
|
Related Articles;
|
|
